Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

47.61USD
2 Mar 2015
Change (% chg)

$-0.14 (-0.29%)
Prev Close
$47.75
Open
$47.64
Day's High
$47.77
Day's Low
$47.50
Volume
134,024
Avg. Vol
257,114
52-wk High
$49.10
52-wk Low
$41.73

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It is engaged in diabetes care. It has a range of diabetes product portfolio, including a portfolio of modern insulins and the first human once-daily GLP-1 analog. In addition,... (more)

Overall

Beta: 0.97
Market Cap(Mil.): $101,366.80
Shares Outstanding(Mil.): 2,112.56
Dividend: 0.76
Yield (%): 1.59

Financials

  NVO.N Industry Sector
P/E (TTM): 32.37 38.87 40.17
EPS (TTM): 1.48 -- --
ROI: 62.12 16.97 16.27
ROE: 67.46 17.50 17.24
Search Stocks

Novo Nordisk increases NNIT offer price range

COPENHAGEN, March 2 - Denmark's Novo Nordisk has increased the price range for the initial public offering of its IT services unit NNIT , NNIT said on Monday.

02 Mar 2015

CORRECTED-Novo Nordisk has positive trial results for oral GLP-1 drug, shares jump

COPENHAGEN, Feb 20 - Danish drugmaker Novo Nordisk , the world's biggest insulin maker, said on Friday it had received positive results from a phase 2 trial of an oral version of a long-acting GLP-1 for treatment of people with type 2 diabetes.

24 Feb 2015

Novo Nordisk to raise up to $335 million from IT subsidiary's IPO

COPENHAGEN - Danish drugmaker Novo Nordisk expects to raise between 1.7 billion and 2.2 billion Danish crowns ($259-335 million) from a stock market listing for NNIT [IPO-NNIT.CO], its information technology services subsidiary.

23 Feb 2015

UPDATE 2-Novo Nordisk to raise up to $335 mln from IT subsidiary's IPO

COPENHAGEN, Feb 23 - Danish drugmaker Novo Nordisk expects to raise between 1.7 billion and 2.2 billion Danish crowns ($259-335 million) from a stock market listing for NNIT, its information technology services subsidiary.

23 Feb 2015

Novo Nordisk has positive trial results for oral diabetes drug, shares jump

COPENHAGEN - Danish drugmaker Novo Nordisk, the world's biggest insulin maker, said on Friday it had received positive results from a Phase II trial of an oral version of a long-acting GLP-1 drug for treatment of people with type 2 diabetes.

20 Feb 2015

CORRECTED-Novo Nordisk has positive trial results for oral GLP-1 drug, shares jump

COPENHAGEN, Feb 20 - Danish drugmaker Novo Nordisk , the world's biggest insulin maker, said on Friday it had received positive results from a phase 2 trial of an oral version of a long-acting GLP-1 for treatment of people with type 2 diabetes.

20 Feb 2015

BRIEF-Novo Nordisk completes phase 2 for an oral formulation of long-acting GLP-1

** Says it has successfully completed phase 2 trial for OG217SC; an oral formulation of long-acting glp-1 analogue semaglutide

20 Feb 2015

BRIEF-Carlsberg to propose Novo Nordisk CEO as deputy chairman

* Says Novo Nordisk CEO Lars Rebien Sørensen will be proposed to join board to replace Deputy Chairman Jess Søderberg Source text for Eikon: Further company coverage: (Reporting By Martinne Geller)

11 Feb 2015

UPDATE 2-Novo Nordisk plans market listing for IT business within five weeks

* IPO could value IT business at up to $760 mln (Adds chairman and CEO quotes, analysts, background)

09 Feb 2015

Novo Nordisk's IT unit to be listed in 4-5 weeks - CFO

COPENHAGEN, Feb 9 - Denmark's Novo Nordisk plans to list its IT services unit NNIT on Copenhagen's stock exchange within the coming four to five weeks, it said on Monday.

09 Feb 2015

Competitors

  Price Chg
Sanofi SA (SASY.PA) €86.40 --
Eli Lilly and Co (LLY.N) $71.12 +0.95

Earnings vs. Estimates

Search Stocks